Intellia disclosed that an elderly patient treated with its LNP‑delivered CRISPR candidate nexiguran ziclumeran (nex‑z) died after developing severe liver dysfunction, prompting the company to pause dosing and screening across its Phase III MAGNITUDE programs. The company reported the hospitalization occurred roughly 24 days post‑dose; the FDA subsequently imposed a clinical hold on the INDs for both pivotal trials. Intellia said the patient was in his early 80s with complicating comorbidities; company leadership is collaborating with external experts and investigators to investigate liver‑related events and to develop risk‑mitigation measures. Regulators and investors are monitoring potential implications for in‑vivo CRISPR platforms and LNP delivery safety profiles.